SCHEMBL20339813

SCHEMBL20339813

N#Cc1c(-c2cccnc2)cc(=O)[nH]c1SCc1cccc(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 12/20 0.55
▸ ADORA1 P30542 4/20 0.52
▸ ADORA2A P29274 2/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ KMO O15229 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30761220 0.90 ACMSD (0.65) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20340158 0.90 ACMSD (0.65) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20340172 0.90 ACMSD (0.61) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20339967 0.85 ACMSD (0.58) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20350857 0.85 ACMSD (0.56) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20340178 0.85 ACMSD (0.65) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20340155 0.84 ACMSD (0.59) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20339531 0.83 ACMSD (0.56) ACMSDADORA1ADORA2AMEN1POLB
SCHEMBL20340157 0.83 ACMSD (0.51) ACMSDADORA1MEN1POLBKMT2A
SCHEMBL31443033 0.83 ACMSD (0.51) ACMSDADORA1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ORSOBIO INC (US) 2025-05-08 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2023-10-10 — — US disclosed
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ORSOBIO, INC. 2021-04-01 — — US disclosed
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ORSOBIO, INC. 2021-04-01 — — US disclosed
WO-2018125983-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed
WO-2018125983-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS MITOBRIDGE, INC. (US) 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ACMSD, ALDH7A1, ALAD ACMSD 1/4885ADORA1 1782/4885ADORA2A 2140/4885
US-20210094916-A1 OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS ALDH7A1, OTC, DDC ACMSD 8/4885ADORA1 2151/4885ADORA2A 2215/4885
US-11780812-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ALDH7A1, ACMSD, AMD1 ACMSD 2/4885ADORA1 1675/4885ADORA2A 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback